This finding among sub-Saharan Africans is quite concerning since dolutegravir is now the preferred first-line HIV treatment worldwide.

This finding comes from a small study of people with highly resistant HIV.

Black study participants switched from a regimen with two nucleoside/nucleotide reverse transcriptase inhibitors plus one other HIV drug.

Extended follow-up confirms that the long-acting monoclonal antibody works well for people with highly resistant HIV.

The novel attachment inhibitor led to viral suppression in 60% of people with extensive prior treatment.

A handful of such cases have been reported since Truvada was approved as pre-exposure prophylaxis in 2012.

Researchers are surprised and concerned that a strain of HIV that is so broadly resistant to treatment even has the capacity to transmit.

The novel attachment inhibitor led to viral suppression in 60% of people with extensive prior treatment.

A recent analysis suggested that only one in four people on antiretroviral treatment take 95% or more of their doses.

ViiV applies for FDA approval of HIV drug fostemsavir